BioSpace News Archive

Tiziana Life Sciences Ltd., a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD, RPh as its new Chief Operating Officer.

Compugen Ltd. announced that on June 12, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550.

Can-Fite BioPharma Ltd. announced that it is doing all the preparatory work for an FDA Investigational New Drug submission for the treatment of pancreatic carcinoma with Namodenoson.

PECA Labs, a medical device company reimagining vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, announced the successful first-in-human implant of the MASA Valve.

Autifony Therapeutics Limited announced that a Phase Ib trial of AUT00201, a potent and selective modulator of Kv3 ion channels, is enrolling patients with Myoclonus Epilepsy and Ataxia due to Potassium Channel Mutation or MEAK at the Hospital of the University of Pennsylvania.

VIVOLTA, a world leader in the development and manufacturing of electrospun medical products, announced that it has raised €7M in a new funding round with participation from existing shareholders and the Dutch government’s NXTGEN HIGHTECH growth fund.

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, announced that Dankook University Hospital in Cheonan, South Korea, is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that on June 11, 2023, the compensation committee of BridgeBio’s board of directors granted 14 new employees restricted stock units for an aggregate of 76,800 shares of the Company’s common stock.

Sensei Biotherapeutics, Inc. announced that the Company will host a virtual KOL event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors,” on Tuesday, June 27, 2023 at 2:00 p.m.

Black Diamond Therapeutics, Inc. announced the promotion of Melanie Morrison from Senior Vice President, Development Operations to Chief Development Officer.